TITLE

Vaccine antibodies correlated with protection against HSV-1

AUTHOR(S)
Shafer, Emily
PUB. DATE
January 2014
SOURCE
Infectious Disease News;Jan2014, Vol. 27 Issue 1, p21
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports that antibodies to herpes simplex virus type 2 glycoprotein D correlated with protection against herpes simplex virus type 1, according to research by Robert Belshe and colleagues that was published in the 2013 issue of "The Journal of Infectious Diseases."
ACCESSION #
94089339

 

Related Articles

  • Early Events in Herpes Simplex Virus Lifecycle with Implications for an Infection of Lifetime. Salameh, Sarah; Sheth, Urmi; Shukla, Deepak // Open Virology Journal;2012, Vol. 6, p1 

    Affecting a large percentage of human population herpes simplex virus (HSV) types -1 and -2 mainly cause oral, ocular, and genital diseases. Infection begins with viral entry into a host cell, which may be preceded by viral "surfing" along filopodia. Viral glycoproteins then bind to one or more...

  • Better Neutralization of Herpes Simplex Virus Type 1 (HSV-1) Than HSV-2 by Antibody From Recipients of GlaxoSmithKline HSV-2 Glycoprotein D2 Subunit Vaccine. Awasthi, Sita; Belshe, Robert B.; Friedman, Harvey M. // Journal of Infectious Diseases;Aug2014, Vol. 210 Issue 4, p571 

    The Herpevac Trial evaluated a herpes simplex virus type 2 (HSV-2) glycoprotein D (gD2) subunit vaccine to prevent genital herpes. Unexpectedly, the vaccine protected against genital HSV-1 infection but not genital HSV-2 infection. We evaluated sera from 30 women seronegative for HSV-1 and HSV-2...

  • Rising incidence and prevalence of herpes simplex type 2 infection in a cohort of 26 year old New Zealanders. Eberhart-Phillips, Jason E; Dickson, Nigel P; Paul, Charlotte; Herbison, G Peter; Taylor, Janette; Cunningham, Anthony L // Sexually Transmitted Infections;Oct2001, Vol. 77 Issue 5, p353 

    Objectives: To examine changes in the incidence and prevalence of herpes simplex type 2 (HSV-2) infection in a birth cohort of 26 year old New Zealanders in whom seroprevalence had been measured at 3.4% at age 21. Methods: Sen from 869 cohort members were tested using an indirect IgG enzyme...

  • Live-Attenuated HSV-2 ICP0- Virus Elicits 10 to 100 Times Greater Protection against Genital Herpes than a Glycoprotein D Subunit Vaccine. Halford, William P.; PĆ¼schel, Ringo; Gershburg, Edward; Wilber, Andrew; Gershburg, Svetlana; Rakowski, Brandon // PLoS ONE;2011, Vol. 6 Issue 3, p1 

    Glycoprotein D (gD-2) is the entry receptor of herpes simplex virus 2 (HSV-2), and is the immunogen in the pharmaceutical industry's lead HSV-2 vaccine candidate. Efforts to prevent genital herpes using gD-2 subunit vaccines have been ongoing for 20 years at a cost in excess of $100 million. To...

  • Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. Cowan, Frances M.; Johnson, Anne M.; Ashley, Rhoda; Corey, Lawrence; Mindel, Adrian // BMJ: British Medical Journal (International Edition);11/19/94, Vol. 309 Issue 6965, p1325 

    Assesses the suitability of herpes simplex virus types 2 as a serological marker of sexual behavior in London population in England. Epidemiology of antibody to herpes simplex virus type 2; Association of antibody with sexual orientation and years of sexual activity of population; Prevalence of...

  • Virology: Back to the HSV drawing board. Molloy, Sheilagh // Nature Reviews Microbiology;Feb2012, Vol. 10 Issue 2, p82 

    The article discusses the glycoprotein D (Gd)-based vaccine field trial against the herpes simplex virus type 2 (HSV-2) which references the study "Efficacy results of a trial of a herpes simplex vaccine," by R. B. Belshe and colleagues in the 2012 issue of "New England Journal of Medicine."

  • Efficacy Results of a Trial of a Herpes Simplex Vaccine. Belshe, Robert B.; Leone, Peter A.; Bernstein, David I.; Wald, Anna; Levin, Myron J.; Stapleton, Jack T.; Gorfinkel, Iris; Morrow, Rhoda L. Ashley; Ewell, Marian G.; Stokes-Riner, Abbie; Dubin, Gary; Heineman, Thomas C.; Schulte, Joann M.; Deal, Carolyn D. // New England Journal of Medicine;1/5/2012, Vol. 366 Issue 1, p34 

    Background: Two previous studies of a herpes simplex virus type 2 (HSV-2) subunit vaccine containing glycoprotein D in HSV-discordant couples revealed 73% and 74% efficacy against genital disease in women who were negative for both HSV type 1 (HSV-1) and HSV-2 antibodies. Efficacy was not...

  • Sorting out the new HSV type specific antibody tests. Ashley, Rhoda L. // Sexually Transmitted Infections;Aug2001, Vol. 77 Issue 4, p232 

    This review will delineate performance characteristics and limitations, as far as they are known, of the new glycoprotein G based, type specific HSV serologies. Several of these tests have been FDA approved in the United States for use in adults. With the departure of Gull/Meridian from the HSV...

  • The first immunoglobulin-like domain of porcine nectin-1 is sufficient to confer resistance to pseudorabies virus infection in transgenic mice. Ono, E.; Tomioka, Y.; Watanabe, Y.; Amagai, K.; Taharaguchi, S.; Glenisson, J.; Cherel, P. // Archives of Virology;Sep2006, Vol. 151 Issue 9, p1827 

    Nectin-1 is an alphaherpesvirus receptor that binds to virion glycoprotein D (gD). Porcine nectin-1 mediates entry of pseudorabies virus (PRV), herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), and bovine herpesvirus type 1 (BHV-1). The gD-binding domain of nectin-1 is the first or...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics